Compare BNTC & FFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNTC | FFA |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.0M | 440.1M |
| IPO Year | 2020 | 2004 |
| Metric | BNTC | FFA |
|---|---|---|
| Price | $10.68 | $21.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $27.67 | N/A |
| AVG Volume (30 Days) | ★ 153.2K | 28.4K |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $15.00 |
| 52 Week High | $17.15 | $22.31 |
| Indicator | BNTC | FFA |
|---|---|---|
| Relative Strength Index (RSI) | 43.32 | 43.23 |
| Support Level | $10.10 | $21.59 |
| Resistance Level | $14.13 | $21.89 |
| Average True Range (ATR) | 0.71 | 0.25 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 54.71 | 27.08 |
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.